Abstract
Psoriasis is a common (1-3% of the population worldwide), multifactorial, immune-mediated chronic skin disease. In psoriasis pathogenesis an over-reaction of local innate immune response initiates inflammation with subsequent involvement of adaptive immune response leading to the production of a panel of cytokines, chemokines and growth factors leading to epidermal hyperplasia. Recently, IL-21 has been involved in this process as this cytokine is overexpressed in psoriatic skin and can cause epidermal hyperplasia and inflammation when injected intradermally into mice. Moreover blockade of IL-21 with a human antibody against IL-21 reduces the epidermal thickness and the expression of Th1 and Th17 genes in the well-characterized model of human psoriasis-xenograft mouse. Therefore, the inhibition of this cytokine may be therapeutically effective in the treatment of psoriasis. Here we will review recent data on psoriasis pathogenesis focusing on the role of IL-21 as novel therapeutic target.
Keywords: IL-21, Psoriasis, Th17, biologics, fusion proteins, therapy, immune-mediated chronic, cytokines, chemokines, epidermal hyperplasia, human antibody, cytokine, novel therapeutic target, molecular mechanisms, immunosuppressive drugs.
Current Pharmaceutical Biotechnology
Title:Psoriasis, from Pathogenesis to Therapeutic Strategies: IL-21 as a Novel Potential Therapeutic Target
Volume: 13 Issue: 10
Author(s): Elisabetta Botti, Giulia Spallone, Roberta Caruso, Giovanni Monteleone, Sergio Chimenti and Antonio Costanzo
Affiliation:
Keywords: IL-21, Psoriasis, Th17, biologics, fusion proteins, therapy, immune-mediated chronic, cytokines, chemokines, epidermal hyperplasia, human antibody, cytokine, novel therapeutic target, molecular mechanisms, immunosuppressive drugs.
Abstract: Psoriasis is a common (1-3% of the population worldwide), multifactorial, immune-mediated chronic skin disease. In psoriasis pathogenesis an over-reaction of local innate immune response initiates inflammation with subsequent involvement of adaptive immune response leading to the production of a panel of cytokines, chemokines and growth factors leading to epidermal hyperplasia. Recently, IL-21 has been involved in this process as this cytokine is overexpressed in psoriatic skin and can cause epidermal hyperplasia and inflammation when injected intradermally into mice. Moreover blockade of IL-21 with a human antibody against IL-21 reduces the epidermal thickness and the expression of Th1 and Th17 genes in the well-characterized model of human psoriasis-xenograft mouse. Therefore, the inhibition of this cytokine may be therapeutically effective in the treatment of psoriasis. Here we will review recent data on psoriasis pathogenesis focusing on the role of IL-21 as novel therapeutic target.
Export Options
About this article
Cite this article as:
Botti Elisabetta, Spallone Giulia, Caruso Roberta, Monteleone Giovanni, Chimenti Sergio and Costanzo Antonio, Psoriasis, from Pathogenesis to Therapeutic Strategies: IL-21 as a Novel Potential Therapeutic Target, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273281
DOI https://dx.doi.org/10.2174/138920112802273281 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis
Vascular Disease Prevention (Discontinued) Medicinal Properties of Neem Leaves: A Review
Current Medicinal Chemistry - Anti-Cancer Agents P-Selectin Antagonism in Inflammatory Disease
Current Pharmaceutical Design Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Epigenetics in Multiple Sclerosis: Molecular Mechanisms and Dietary Intervention
Central Nervous System Agents in Medicinal Chemistry Mitochondria-Targeted Drugs
Current Molecular Pharmacology Biomarkers in Unstable Carotid Plaque: Physiopathology and Prediction
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology The Effects of Ageing on Proliferation Potential, Differentiation Potential and Cell Surface Characterisation of Human Mesenchymal Stem Cells
Current Stem Cell Research & Therapy A Review of Eugenol-based Nanomedicine: Recent Advancements
Current Bioactive Compounds Hepatocellular Carcinoma Outside of the Milan Criteria
Current Cancer Therapy Reviews Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Macrophage Differentiation to Foam Cells
Current Pharmaceutical Design Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets The Mechanism of Dead-in-Bed Syndrome and Other Sudden Unexplained Nocturnal Deaths
Current Diabetes Reviews Brain Drug Delivery System: An Overview
Current Drug Therapy Gene Electrotransfer: A Mechanistic Perspective
Current Gene Therapy Kv1.3 Lymphocyte Potassium Channel Inhibition as a Potential Novel Therapeutic Target in Acute Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Measuring the Impact of Psychoactive Substance on Health-Related Quality of Life: An Update
Current Drug Abuse Reviews